Progress in CNS Drug Development Outside Dementia

8:30 AM - 9:40 AM, Wednesday, October 23, 2019 ・ 2nd Floor
Recent studies from the National MS Society have estimated that nearly one million people in the United States are suffering from Multiple Sclerosis. Another thirty thousand suffer from ALS, and thousands more from other CNS disorders that remain without a cure. In order to address the unmet medical needs of this patient population, dozens of companies from across the biotechnology industry are involved in late-phase clinical trials that are exploring the efficacy of different drug treatments on a variety of CNS disorders. On the investment side of the equation, neurology companies had the third highest number of biopharma deals in the first half of 2019, with over $800 million invested, according to the Silicon Valley Bank Mid-Year Report 2019. Hear from researchers and biotech executives involved in CNS drug development to gain insight into how the industry is expanding and the current clinical trials that have the potential to provide life-changing therapeutic solutions.
Speakers
photo
Vice President
Accelerator Life Science Partners
Tao Huang
President and CEO;Venture Partner
NeuCyte;Cenova Capital
photo
Chief Business Officer
Impel NeuroPharma
photo
Founder and CEO; Director
Retrotope
photo
Chief Medical Officer/CMO-in-Residence
BridgeBio Pharma